Outcomes of balloon aortic valvuloplasty in contemporary practice: A single-center observational study
BACKGROUND: Balloon aortic valvuloplasty (BAV) remains a vital tool as a bridge to definitive treatment, a palliative therapy, or a stabilizing procedure for hemodynamically unstable patients. AIMS: Our aim was to characterize patients undergoing BAV and identify predictors of procedural success, major adverse cardiovascular and cerebrovascular events, and in-hospital mortality. METHODS: This retrospective, single-center registry embraced consecutive patients undergoing BAV between 2010 and 2022. Procedural success was defined as mean pressure gradient reduction > 10 mm Hg. Major adverse cardiovascular and cerebrovascular events was the primary composite endpoint. RESULTS: Among 136 patients (57 men [41.9%]; mean [standard deviation] age 78.5 [8.9] years), BAV was performed as: a bridge to transcatheter aortic valve implantation (n = 42, 30.9%), palliative procedure (n = 49, 36.0%), prognostic procedure during transcatheter aortic valve implantation qualification (n = 33, 24.3%). Sixteen patients underwent percutaneous coronary intervention (14 before [10.3%] and 2 during BAV [1.5%]). Procedural success was reported in 60 patients (44.1%) and independently associated with a higher mean pressure gradient (odds ratio [OR], 1.09; 95% confidence interval: 1.002-1.19; P = 0.04). Major adverse cardiovascular and cerebrovascular events occurred in 23 patients (16.9%), was independently predicted by a higher maximal aortic valve gradient (OR, 1.02; P = 0.014) and need for intubation (OR, 15.5; P = 0.003). In-hospital mortality was 6.6%, with precedent percutaneous coronary intervention being its independent predictor (OR, 32.0; P = 0.015). Patients after successful BAV more frequently underwent subsequent aortic valve replacement. CONCLUSIONS: Balloon aortic valvuloplasty remains a valuable procedure, particularly as a bridge to definitive treatment. Major adverse cardiovascular and cerebrovascular events and mortality risk remains significant, highlighting the fragile nature of the patients' population.
Authors
- Zofia Kampka (ORCID: https://orcid.org/0000-0002-9855-9333)
- Damian Hudziak (ORCID: https://orcid.org/0000-0003-3715-0697)
- Marek Grabka (ORCID: https://orcid.org/0000-0002-1941-4356)
- Maciej Wybraniec (ORCID: https://orcid.org/0000-0003-1151-8385)
- Radosław Gocoł (ORCID: https://orcid.org/0000-0002-2097-1918)
- Krystian Wita (ORCID: https://orcid.org/0000-0001-9772-6729)
- Tomasz Bochenek (ORCID: https://orcid.org/0000-0001-9915-7267)
- Kamil Górny
- Kamil Jabłoński
- Wojciech Żakiewicz
- Katarzyna Szlachetka
- Michał Lelek
- Katarzyna Mizia-Stec
- Aleksandra Golec (ORCID: https://orcid.org/0009-0004-9105-350X)
- Julia Jung
- Emilia Koziara (ORCID: https://orcid.org/0009-0005-4454-6085)
Institutions
- Medical University of Silesia (PL)
- Silesian Center for Heart Disease (PL)
- ERN GUARD-Heart (NL)
Publication Details
- Journal
- Kardiologia Polska
- Published
- 2026-07-28
- DOI
- https://doi.org/10.33963/v.phj.113887
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00